Skip to main content
Erschienen in: International Urology and Nephrology 5/2016

18.01.2016 | Nephrology - Original Paper

Is low magnesium a clue to arteriovenous fistula complications in hemodialysis?

verfasst von: Radojica V. Stolic, Aleksandar N. Jovanovic, Goran Z. Trajkovic, Mirjana M. Kostic, Andrijana M. Odalovic, Sasa R. Sovtic, Maja V. Sipic, Slavica D. Pajovic, Zorica N. Sojevic-Timotijevic

Erschienen in: International Urology and Nephrology | Ausgabe 5/2016

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Magnesium insufficiency is a pro-atherogenic factor involved in endothelial dysfunction, atherosclerosis, and vascular calcification. Our aim was to examine the role of magnesium in the development of arteriovenous fistula complications in hemodialysis.

Methods

This was a retrospective clinical investigation of data from 88 patients who were divided into two groups: those with and without arteriovenous fistula complications. We examined the influence of sex, demographics, and clinical and laboratory parameters. The existence of fistula stenosis was determined by measuring Doppler flow, while B-mode ultrasound was used to detect plaques and evaluate the carotid artery intima–media thickness.

Results

Patients with arteriovenous fistula complications had significantly higher leukocyte counts (p = 0.03), platelet counts (p = 0.03), phosphate concentrations (p = 0.044), and alkaline phosphatase concentrations (p = 0.04). Patients without complications had significantly greater blood flow through the arteriovenous fistula (p < 0.0005), higher magnesium concentrations (p = 0.004), and a lower carotid artery intima–media thickness (p = 0.037). The magnesium level was inversely correlated with leukocyte (p = 0.028) and platelet (p = 0.016) counts. The magnesium concentration was significantly lower in patients with carotid artery plaques (p = 0.03). Multiple linear regression, using magnesium as the dependent variable in patients with arteriovenous fistula complications, indicated statistically significant correlations with platelet (p = 0.005) and leukocyte (p = 0.027) counts and carotid plaques (p = 0.045).

Conclusions

Hypomagnesemia is a significant pro-atherogenic factor and an important predictor of arteriovenous fistula complications.
Literatur
1.
Zurück zum Zitat Courivaud C, Davenport A (2013) Magnesium and the risk of all-cause and cardiac mortality in hemodialysis patients: Agent provocateur or innocent bystander? Kidney Int 85:17–20. doi:10.1038/ki.2013.301 CrossRef Courivaud C, Davenport A (2013) Magnesium and the risk of all-cause and cardiac mortality in hemodialysis patients: Agent provocateur or innocent bystander? Kidney Int 85:17–20. doi:10.​1038/​ki.​2013.​301 CrossRef
5.
Zurück zum Zitat Ishimura E, Okuno S, Kitatani K, Tsuchida T, Yamakawa T, Shioi A, Inaba M, Nishizawa Y (2007) Significant association between the presence of peripheral vascular calcification and lower serum magnesium in hemodialysis patients. Clin Nephrol 68:222–227. doi:10.5414/CNP68222 CrossRefPubMed Ishimura E, Okuno S, Kitatani K, Tsuchida T, Yamakawa T, Shioi A, Inaba M, Nishizawa Y (2007) Significant association between the presence of peripheral vascular calcification and lower serum magnesium in hemodialysis patients. Clin Nephrol 68:222–227. doi:10.​5414/​CNP68222 CrossRefPubMed
6.
Zurück zum Zitat Meema HE, Oreopoulos DG, Rapoport A (1987) Serum magnesium level and arterial calcification in end-stage renal disease. Kidney Int 32:388–394CrossRefPubMed Meema HE, Oreopoulos DG, Rapoport A (1987) Serum magnesium level and arterial calcification in end-stage renal disease. Kidney Int 32:388–394CrossRefPubMed
9.
Zurück zum Zitat Pakfetrat M, Sharifpour S, Malekmakan L, Jahromi SE, Roozbeh J, Aslani A (2014) The effect of magnesium oxide on hyperphosphatemia in female hemodialysis patients. Women’s Health Bull 1(2):e20048 Pakfetrat M, Sharifpour S, Malekmakan L, Jahromi SE, Roozbeh J, Aslani A (2014) The effect of magnesium oxide on hyperphosphatemia in female hemodialysis patients. Women’s Health Bull 1(2):e20048
11.
Zurück zum Zitat Stolić R, Trajković G, Perić V, Jovanović A, Subarić-Gorgieva G (2007) Impact of arteriosclerosis on the functioning of arteriovenous fistula for hemodialysis. Vojnosanit Pregl 64:13–18 (Serbian) CrossRefPubMed Stolić R, Trajković G, Perić V, Jovanović A, Subarić-Gorgieva G (2007) Impact of arteriosclerosis on the functioning of arteriovenous fistula for hemodialysis. Vojnosanit Pregl 64:13–18 (Serbian) CrossRefPubMed
12.
Zurück zum Zitat Stolić R, Mitrović S, Stolić D, Mitić N (2010) Early pathohistological changes in dysfunction of arteriovenous fistula for hemodialysis. Vojnosanit Pregl 67:65–68 (Serbian) CrossRefPubMed Stolić R, Mitrović S, Stolić D, Mitić N (2010) Early pathohistological changes in dysfunction of arteriovenous fistula for hemodialysis. Vojnosanit Pregl 67:65–68 (Serbian) CrossRefPubMed
13.
Zurück zum Zitat Papagianni A, Kalovoulos M, Kirmizis D, Vainas A, Belechri AM, Alexopoulos E, Memmos D (2003) Carotid atherosclerosis is associated with inflammation and endothelial cell adhesion molecules in chronic haemodialysis patients. Nephrol Dial Transplant 18:113–119. doi:10.1093/ndt/18.1.113 CrossRefPubMed Papagianni A, Kalovoulos M, Kirmizis D, Vainas A, Belechri AM, Alexopoulos E, Memmos D (2003) Carotid atherosclerosis is associated with inflammation and endothelial cell adhesion molecules in chronic haemodialysis patients. Nephrol Dial Transplant 18:113–119. doi:10.​1093/​ndt/​18.​1.​113 CrossRefPubMed
14.
Zurück zum Zitat Geroulakos G, O’Gorman DJ, Kalodiki E, Sheridan DJ, Nicolaides SN (1994) The carotid intima-media thickness as a marker of the presence of severe symptomatic coronary artery disease. Eur Heart J 15:781–785PubMed Geroulakos G, O’Gorman DJ, Kalodiki E, Sheridan DJ, Nicolaides SN (1994) The carotid intima-media thickness as a marker of the presence of severe symptomatic coronary artery disease. Eur Heart J 15:781–785PubMed
16.
Zurück zum Zitat Sakaguchi Y, Fujii N, Shoji T, Hayashi T, Rakugi H, Isaka Y (2013) Hypomagnesemia is a significant predictor of cardiovascular and non-cardiovascular mortality in patients undergoing hemodialysis. Kidney Int 85:174–181. doi:10.1038/ki.2013.327 CrossRefPubMed Sakaguchi Y, Fujii N, Shoji T, Hayashi T, Rakugi H, Isaka Y (2013) Hypomagnesemia is a significant predictor of cardiovascular and non-cardiovascular mortality in patients undergoing hemodialysis. Kidney Int 85:174–181. doi:10.​1038/​ki.​2013.​327 CrossRefPubMed
18.
Zurück zum Zitat Kanbay M, Yilmaz MI, Apetrii M, Saglam M, Yaman H, Unal HU et al (2012) Relationship between serum magnesium levels and cardiovascular events in chronic kidney disease patients. Am J Nephrol 36:228–237. doi:10.1159/000341868 CrossRefPubMed Kanbay M, Yilmaz MI, Apetrii M, Saglam M, Yaman H, Unal HU et al (2012) Relationship between serum magnesium levels and cardiovascular events in chronic kidney disease patients. Am J Nephrol 36:228–237. doi:10.​1159/​000341868 CrossRefPubMed
19.
Zurück zum Zitat Tzanakis I, Virvidakis K, Tsomi A, Mantakas E, Girousis N, Karefyllakis N, Papadaki A, Kallivretakis N, Mountokalakis T (2004) Intra-and extracellular magnesium levels and atheromatosis in haemodialysis patients. Magnes Res 17:102–108PubMed Tzanakis I, Virvidakis K, Tsomi A, Mantakas E, Girousis N, Karefyllakis N, Papadaki A, Kallivretakis N, Mountokalakis T (2004) Intra-and extracellular magnesium levels and atheromatosis in haemodialysis patients. Magnes Res 17:102–108PubMed
22.
23.
Zurück zum Zitat Mortazavi M, Moeinzadeh F, Saadatnia M, Shahidi S, McGee JC, Minagar A (2013) Effect of magnesium supplementation on carotid intima-media thickness and flow-mediated dilatation among hemodialysis patients: a double-blind, randomized, placebo-controlled trial. Eur Neurol 69:309–316. doi:10.1159/000346427 CrossRefPubMed Mortazavi M, Moeinzadeh F, Saadatnia M, Shahidi S, McGee JC, Minagar A (2013) Effect of magnesium supplementation on carotid intima-media thickness and flow-mediated dilatation among hemodialysis patients: a double-blind, randomized, placebo-controlled trial. Eur Neurol 69:309–316. doi:10.​1159/​000346427 CrossRefPubMed
26.
Zurück zum Zitat Polkinghorne KR, Lau KKP, Saunder A, Atkins RC, Kerr PG (2006) Does monthly native arteriovenous fistula blood-flow surveillance detect significant stenosis—a randomized controlled trial. Nephrol Dial Transplant 21:2498–2506. doi:10.1093/ndt/gfl242 CrossRefPubMed Polkinghorne KR, Lau KKP, Saunder A, Atkins RC, Kerr PG (2006) Does monthly native arteriovenous fistula blood-flow surveillance detect significant stenosis—a randomized controlled trial. Nephrol Dial Transplant 21:2498–2506. doi:10.​1093/​ndt/​gfl242 CrossRefPubMed
29.
Zurück zum Zitat Ortega O, Rodriguez I, Cobo G, Hinostroza J, Gallar P, Mon C, et al (2013) Lack of influence of serum magnesium levels on overall mortality and cardiovascular outcomes in patients with advanced chronic kidney disease. ISRN Nephrol. Article ID 191786. doi:10.5402/2013/191786 Ortega O, Rodriguez I, Cobo G, Hinostroza J, Gallar P, Mon C, et al (2013) Lack of influence of serum magnesium levels on overall mortality and cardiovascular outcomes in patients with advanced chronic kidney disease. ISRN Nephrol. Article ID 191786. doi:10.​5402/​2013/​191786
31.
Zurück zum Zitat Stolic RV, Trajkovic GZ, Kostic M, Stolic DZ, Miric DJ, Kisic BM et al (2014) Predictive value of serum myeloperoxidase activity for thrombosis of arteriovenous fistulas. Hemodial Int 18:680–685. doi:10.1111/hdi.12155 CrossRefPubMed Stolic RV, Trajkovic GZ, Kostic M, Stolic DZ, Miric DJ, Kisic BM et al (2014) Predictive value of serum myeloperoxidase activity for thrombosis of arteriovenous fistulas. Hemodial Int 18:680–685. doi:10.​1111/​hdi.​12155 CrossRefPubMed
Metadaten
Titel
Is low magnesium a clue to arteriovenous fistula complications in hemodialysis?
verfasst von
Radojica V. Stolic
Aleksandar N. Jovanovic
Goran Z. Trajkovic
Mirjana M. Kostic
Andrijana M. Odalovic
Sasa R. Sovtic
Maja V. Sipic
Slavica D. Pajovic
Zorica N. Sojevic-Timotijevic
Publikationsdatum
18.01.2016
Verlag
Springer Netherlands
Erschienen in
International Urology and Nephrology / Ausgabe 5/2016
Print ISSN: 0301-1623
Elektronische ISSN: 1573-2584
DOI
https://doi.org/10.1007/s11255-015-1207-6

Weitere Artikel der Ausgabe 5/2016

International Urology and Nephrology 5/2016 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

SGLT2-Inhibitoren und GLP-1-Rezeptoragonisten im Schlagabtausch

16.05.2024 DDG-Jahrestagung 2024 Kongressbericht

Wer hat die Nase vorn – SGLT2-Inhibitoren oder GLP-1-Rezeptoragonisten? Diese Frage diskutierten zwei Experten in einer Session auf dem diesjährigen Diabetes-Kongress.

Betalaktam-Allergie: praxisnahes Vorgehen beim Delabeling

16.05.2024 Pädiatrische Allergologie Nachrichten

Die große Mehrheit der vermeintlichen Penicillinallergien sind keine. Da das „Etikett“ Betalaktam-Allergie oft schon in der Kindheit erworben wird, kann ein frühzeitiges Delabeling lebenslange Vorteile bringen. Ein Team von Pädiaterinnen und Pädiatern aus Kanada stellt vor, wie sie dabei vorgehen.

Alphablocker schützt vor Miktionsproblemen nach der Biopsie

16.05.2024 alpha-1-Rezeptorantagonisten Nachrichten

Nach einer Prostatabiopsie treten häufig Probleme beim Wasserlassen auf. Ob sich das durch den periinterventionellen Einsatz von Alphablockern verhindern lässt, haben australische Mediziner im Zuge einer Metaanalyse untersucht.

Delir bei kritisch Kranken – Antipsychotika versus Placebo

16.05.2024 Delir nicht substanzbedingt Nachrichten

Um die Langzeitfolgen eines Delirs bei kritisch Kranken zu mildern, wird vielerorts auf eine Akuttherapie mit Antipsychotika gesetzt. Eine US-amerikanische Forschungsgruppe äußert jetzt erhebliche Vorbehalte gegen dieses Vorgehen. Denn es gibt neue Daten zum Langzeiteffekt von Haloperidol bzw. Ziprasidon versus Placebo.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.